Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis.
Demyelinating disease: CSF analysis could aid prediction of conversion from optic neuritis to multiple sclerosis in children.
SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function.
Effect of light finger touch in balance control of individuals with multiple sclerosis.
[Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks(review)].
Interferon Beta and Long-term Disability in Multiple Sclerosis-Reply.
Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis.
Loss of astrocytic leptin signaling worsens experimental autoimmune encephalomyelitis.
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Prevalence of Classic and Non-Classic Antiphospholipid Antibodies in Multiple Sclerosis.
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β
Validity of visual perceptive computing for static posturography in patients with multiple sclerosis.
Soluble Tumor Necrosis Factor Receptor 1 Released by Skin-Derived Mesenchymal Stem Cells Is Critical for Inhibiting Th17 Cell Differentiation.
Analysis of CH25H in multiple sclerosis and neuromyelitis optica.
Google Trends: new evidence for seasonality of multiple sclerosis.
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.
[A case of early systemic lupus erythematosus complicated with optic neuritis].
Impaired functional integration in multiple sclerosis: a graph theory study.
Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica.
Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis.
Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis.
An updated role of microRNA-124 in central nervous system disorders: a review.
The Clinical Characteristics of Primary Sjogren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China: A STROBE-Compliant Article.
[Pulmonary lymphangioleiomyomatosis of unusual revelation during multiple sclerosis].
Evasion of Antiviral Innate Immunity by Theiler's Virus L* Protein through Direct Inhibition of RNase L.
Pages
« first
‹ previous
…
568
569
570
571
572
573
574
575
576
…
next ›
last »